Skip to content

The effect of different amounts of assisted reproductive drugs in endometriosis patients

Comparing double dose and tirple dose of GNRH agonists in Endometriosis triggering undergoing ART cycle

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200925048836N2
Enrollment
80
Registered
2022-01-21
Start date
2022-02-18
Completion date
Unknown
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility.

Interventions

Intervention 1: In intervention group 1, on day 2 or 3 of the menstrual cycle, controlled ovarian stimulation with recombinant FSH (Gonal-f, merck senoro) at a dose of 175-112.5 IU / DAY will be perfo

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 35 Years

Inclusion criteria

Inclusion criteria: Women with a definite diagnosis of endometriosis based on pathology report aged between 21 and 35 years, the first period of using ART method, normal serum FSH concentration in primary follicular phase , AMH>0.5, presence of both ovary , having the ART use indication that they are willing to participate in the study.

Exclusion criteria

Exclusion criteria: history of uterine and ovary surgery poly cystic ovarian syndrome triggering with HCG severe fertilizing disorder in spouse patient with hypo gonadotrpic hypogonadism and uterine abnormality

Design outcomes

Primary

MeasureTime frame
Oocyte maturation. Timepoint: Before and after treatment. Method of measurement: Transvaginal sonography.

Secondary

MeasureTime frame
Oocyte yield. Timepoint: Before and after treatment. Method of measurement: Transvaginal sonography and hormonal assay.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAskari Elham

Shiraz University of Medical Sciences

elliaskary_md@yahoo.com+98 71 3233 2365

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026